Ovidrel is a drug owned by Emd Serono Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 16, 2021. Details of Ovidrel's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6706681 | HCG liquid formulations |
Mar, 2021
(3 years ago) |
Expired
|
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(9 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Ovidrel and ongoing litigations to help you estimate the early arrival of Ovidrel generic.
Ovidrel's Litigations
Ovidrel been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 06, 2000, against patent number US6706681. The petitioner , challenged the validity of this patent, with SAMARITANI et al as the respondent. Click below to track the latest information on how companies are challenging Ovidrel's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6706681 | July, 2000 |
Decision
(23 Jan, 2002) | SAMARITANI et al | |
US patents provide insights into the exclusivity only within the United States, but Ovidrel is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ovidrel's family patents as well as insights into ongoing legal events on those patents.
Ovidrel's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ovidrel's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 16, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ovidrel Generics:
There are no approved generic versions for Ovidrel as of now.
About Ovidrel
Ovidrel is a drug owned by Emd Serono Inc. Ovidrel uses Choriogonadotropin Alfa as an active ingredient. Ovidrel was launched by Emd Serono in 2000.
Approval Date:
Ovidrel was approved by FDA for market use on 20 September, 2000.
Active Ingredient:
Ovidrel uses Choriogonadotropin Alfa as the active ingredient. Check out other Drugs and Companies using Choriogonadotropin Alfa ingredient
Dosage:
Ovidrel is available in the following dosage forms - injectable form for subcutaneous use, injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.25MG /0.5ML | INJECTABLE | Prescription | SUBCUTANEOUS |
| 0.25MG/VIAL | INJECTABLE | Discontinued | INJECTION |